The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma

Howard M. Goodman, Bernard L. Harlow, Ellen E. Sheets, Michael G. Muto, Sandra Brooks, Michael Steller, Robert C. Knapp, Ross S. Berkowitz

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Patients with Stage IV epithelial ovarian carcinoma are generally treated in the same manner as are patients with disease confined to the abdomen-cytoreductive surgery followed by combination chemotherapy. Between 1980 and 1990, 35 women with histologically or cytologically documented Stage IV ovarian carcinoma were treated in this fashion. Sixteen women (45%) underwent optimal initial cytoreductive surgery, defined as less than 2 cm maximum residual disease. Eleven of the 19 women undergoing suboptimal initial procedures underwent interval cytoreduction after two to four cycles of chemotherapy, with 7 achieving an optimal status after the interval procedure. Overall, 23 of 35 patients (66%) were successfully cytoreduced to less than 2 cm either initially or at an interval procedure. Thirty-one of the 35 patients received combination regimens containing platinum as part of their initial therapy. Kaplan-Meier survival curves demonstrated no significant difference in survival between those groups of women cytoreduced intervally or initially, or between those groups of women optimally cytoreduced at some point during their initial therapy and those who were not. The 5-year survival for the entire group was less than 5%, with no significantly prolonged survival seen in those patients undergoing successful cytoreduction.

Original languageEnglish (US)
Pages (from-to)367-371
Number of pages5
JournalGynecologic oncology
Issue number3
StatePublished - Sep 1992
Externally publishedYes


Dive into the research topics of 'The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma'. Together they form a unique fingerprint.

Cite this